SG11201810952PA - Lantibiotic variants and uses thereof - Google Patents

Lantibiotic variants and uses thereof

Info

Publication number
SG11201810952PA
SG11201810952PA SG11201810952PA SG11201810952PA SG11201810952PA SG 11201810952P A SG11201810952P A SG 11201810952PA SG 11201810952P A SG11201810952P A SG 11201810952PA SG 11201810952P A SG11201810952P A SG 11201810952PA SG 11201810952P A SG11201810952P A SG 11201810952PA
Authority
SG
Singapore
Prior art keywords
international
drive
july
lantibiotic
gainesville
Prior art date
Application number
SG11201810952PA
Other languages
English (en)
Inventor
Martin Handfield
Johan Kers
Sheela Muley
Melissa Mayo
Jeffrey Colbeck
Robert Sharp
Albert Fosmoe
Anthony Defusco
Original Assignee
Intrexon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Corp filed Critical Intrexon Corp
Publication of SG11201810952PA publication Critical patent/SG11201810952PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01001—Alcohol dehydrogenase (1.1.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Birds (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Environmental Sciences (AREA)
  • Virology (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
SG11201810952PA 2016-07-15 2017-07-14 Lantibiotic variants and uses thereof SG11201810952PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662362809P 2016-07-15 2016-07-15
US201662362788P 2016-07-15 2016-07-15
US201662420328P 2016-11-10 2016-11-10
PCT/US2017/042206 WO2018013967A1 (en) 2016-07-15 2017-07-14 Lantibiotic variants and uses thereof

Publications (1)

Publication Number Publication Date
SG11201810952PA true SG11201810952PA (en) 2019-01-30

Family

ID=59626658

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810952PA SG11201810952PA (en) 2016-07-15 2017-07-14 Lantibiotic variants and uses thereof

Country Status (10)

Country Link
US (1) US20190315814A1 (cg-RX-API-DMAC7.html)
EP (1) EP3484442A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019529344A (cg-RX-API-DMAC7.html)
KR (1) KR20190028746A (cg-RX-API-DMAC7.html)
CN (1) CN109715132A (cg-RX-API-DMAC7.html)
AU (1) AU2017296061B2 (cg-RX-API-DMAC7.html)
CA (1) CA3027673A1 (cg-RX-API-DMAC7.html)
IL (1) IL263682A (cg-RX-API-DMAC7.html)
SG (1) SG11201810952PA (cg-RX-API-DMAC7.html)
WO (1) WO2018013967A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10577399B2 (en) 2016-10-28 2020-03-03 The Texas A&M University System Modified lantibiotics and methods of making and using the modified lantibiotics
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
JP2022085803A (ja) * 2020-11-27 2022-06-08 株式会社三六九 スポット式換気クリーンシステム、並びに可変式フェイスシールド

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US5607672A (en) 1995-06-07 1997-03-04 University Of Florida Research Foundation, Inc. Replacement therapy for dental caries
US6964760B2 (en) 1997-06-10 2005-11-15 University Of Florida Research Foundation Antimicrobial polypeptide, nucleic acid, and methods of use
US20090215985A1 (en) 2005-08-12 2009-08-27 Oragenics, Inc. Differentially protected orthogonal lanthionine technology
EP1915389B1 (en) 2005-08-12 2011-06-08 Oragenics, Inc. Differentially protected orthogonal lanthionine technology
CA2865395A1 (en) * 2012-02-27 2013-09-06 Oragenics, Inc. Variants of the lantibiotic mu1140 and other lantibiotics with improved pharmacological properties and structural features

Also Published As

Publication number Publication date
JP2019529344A (ja) 2019-10-17
WO2018013967A9 (en) 2019-02-28
AU2017296061B2 (en) 2021-07-15
EP3484442A1 (en) 2019-05-22
CN109715132A (zh) 2019-05-03
WO2018013967A1 (en) 2018-01-18
AU2017296061A9 (en) 2019-08-01
US20190315814A1 (en) 2019-10-17
AU2017296061A1 (en) 2019-01-03
CA3027673A1 (en) 2018-01-18
IL263682A (en) 2019-01-31
KR20190028746A (ko) 2019-03-19

Similar Documents

Publication Publication Date Title
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201809064QA (en) Chimeric neurotoxins
SG11201909949XA (en) Targeted immunotolerance
SG11201908171TA (en) Compounds and compositions for treating hematological disorders
SG11201810286WA (en) Variable diameter bioreactors
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201805835WA (en) Modified oncolytic virus
SG11201807025SA (en) Crispr/cas systems for c-1 fixing bacteria
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201805470VA (en) Code and container of system for preparing a beverage or foodstuff
SG11201903833VA (en) Tray system for transfer, counting, storage and disposal of surgical instruments
SG11201407233RA (en) Ethylene oligomerization process
SG11201804589TA (en) Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201907645PA (en) Proteins binding cd123, nkg2d and cd16
SG11201810583WA (en) A bitumen composition comprising a wax mixture consisting of a petroleum slack wax and a fischer-tropsch wax, the use of the wax mixture in bitumen compositions, the use of the bitumen composition in asphalt compositions, asphalt compositions comprising the bitumen composition and the method of producing asphalt pavements thereof
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof
SG11201407988UA (en) Process for improved opioid synthesis
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201803816RA (en) Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease
SG11201903294VA (en) Olefin polymerization process in a gas-phase reactor having three or more polymerization zones
SG11201909837YA (en) Methods for treating lung disorders
SG11201906511SA (en) Compounds and their use in the treatment of schistosomiasis
SG11201909872WA (en) Stability of short path evaporation treated oils